Isturisa denied as non-formulary by Cigna?

Cigna's specific coverage criteria for isturisa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Isturisa as Non-Formulary

A non-formulary denial means Isturisa (osilodrostat) is not included on Cigna's active drug formulary for your specific benefit plan, or is placed at a tier that requires a formulary exception before it can be covered at a meaningful benefit level. For rare endocrine conditions like Cushing's disease, the number of approved agents is small, and a non-formulary placement does not mean the drug is excluded from coverage — it means you must request a formulary exception and demonstrate medical necessity.

Formulary exceptions are routinely granted for Cushing's disease medications when the clinical documentation establishes that formulary alternatives are not appropriate for your individual case.

## Federal Appeal Framework

• Formulary exception right: Under ACA and ERISA regulations, plans must have an exceptions process for non-formulary drugs when a formulary alternative is not medically appropriate for the enrollee.
• ACA §2719 / ERISA §503: If the formulary exception is denied, you have the right to a full internal appeal and, if that fails, to external review by an IRO.
• External review deadline: You generally have approximately four months from the denial notice to request IRO review — confirm your exact deadline on the denial letter.
• Expedited option: Available if your medical condition makes the standard timeline dangerous.

## Concrete Appeal Process and Timeline

1. File a formal formulary exception request with Cigna, supported by the prescriber's documentation that formulary alternatives are clinically inappropriate for your case. 2. If the exception is denied, immediately file a written internal appeal within Cigna's stated deadline (typically 180 days from denial). 3. Cigna must respond to a prospective internal appeal within 30 days, or 60 days for post-service reviews. 4. If denied internally, escalate to IRO external review before your four-month window closes.

## Documentation to Gather

• Diagnosis confirmation: Endocrinology records confirming Cushing's disease — biochemical evaluation, imaging, and clinical notes establishing the active diagnosis.
• Formulary alternative assessment: For each drug on Cigna's formulary that could be considered a comparator, documentation from the chart explaining why it is not appropriate — prior trials with dates and outcomes, tolerability issues, or clinical contraindications documented by the prescriber (not just asserted in a letter).
• Prescriber medical-necessity letter: A letter from the treating endocrinologist that addresses each formulary alternative by name, explains why Isturisa is the medically necessary choice for this patient specifically, and references the FDA-approved prescribing information.
• Clinical severity: Current disease-activity documentation showing the consequences of further treatment delay.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria and any applicable Isturisa medical policy. Then map your evidence:

| Exception Criterion | Patient-Specific Evidence | |---|---| | Formulary alternative is contraindicated or caused adverse effects | [Alternative drug name, dates, chart documentation of outcome] | | Formulary alternative is expected to be ineffective based on individual clinical factors | [Prescriber's documented rationale per chart] | | Isturisa is FDA-approved for the patient's condition | [FDA label reference, approved indication] |

Attach all referenced records. The formulary exception and the subsequent internal appeal are reviewed by different personnel — submit the same complete package to both. A well-documented exception request often resolves the issue before an internal appeal is needed.